Skip to main content
Premium Trial:

Request an Annual Quote

Joe Bernardo

Joe Bernardo has been named chairman of the board of SeraCare Life Sciences. Bernardo is also an operating partner at Linden Capital Partners, the equity investors behind SeraCare. Prior to these roles, he served as president of the next-generation sequencing and oncology division at Thermo Fisher Scientific. He has also worked for Siemens Healthcare, where he was senior vice president of the central lab business unit, and Abbott Laboratories.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.